
|Videos|October 17, 2022
Currently Available Treatment Options for Patients with Higher-Risk Myelodysplastic Syndrome
Author(s)Hetty E. Carraway, MD, Eytan M. Stein, MD
Dr Hetty Carraway reviews the available treatment options for patients with higher-risk MDS, and the biggest challenges of treatment.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
2
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
3
Off-the-Shelf In Vivo BCMA CAR T KLN-1010 Yields Deep R/R Myeloma Responses
4
Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer
5










































